Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navarixin - Ligand Pharmaceuticals/Merck & Co.

Next Previous
X
Search
Drug Profile

Navarixin - Ligand Pharmaceuticals/Merck & Co.

Alternative Names: MK-7123; PS-291822; SCH 527123; SCH 5271234

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacopeia; Schering-Plough
  • Developer Ligand Pharmaceuticals; Merck & Co
  • Class Anti-inflammatories; Antineoplastics; Benzamides; Cyclobutanes
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Asthma; Chronic obstructive pulmonary disease; Psoriasis

Most Recent Events

  • 19 May 2021 Merck completes phase II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia, Canada, South Korea, Israel (PO) (NCT03473925)
  • 19 Feb 2021 Navarixin is still in phase II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Israel (PO) (NCT03473925)
  • 22 Jan 2021 Merck & Co. completes enrolment in its phase II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia, Canada, Israel, South Korea (PO) (NCT03473925)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top